Results 141 to 150 of about 70,337 (231)

Dose Adjustment of Poly (ADP‑Ribose) Polymerase Inhibitors in Patients with Hepatic or Renal Impairment. [PDF]

Drug Des Devel Ther, 2022
Zhao D, Long X, Wang J.
europepmc   +1 more source

ShallowHRD status acts as an effective prognostic predictor in ovarian cancer patients treated by poly (ADP-ribose) polymerase inhibitors (PARPis). [PDF]

J Cancer Res Clin Oncol, 2023
Guo Y, He X, Tan Y, Liu J, Chen H, Huang Y, Zhang C, Tao Y, Chen S.   +8 more
europepmc   +1 more source

Stellettin B renders glioblastoma vulnerable to poly (ADP-ribose) polymerase inhibitors via suppressing homology-directed repair. [PDF]

Signal Transduct Target Ther, 2023
Peng X, Wang Y, Zhang S, Tao Z, Dai Y, Claret FX, Elkabets M, Lin HW, Chen ZS, Kong D.   +9 more
europepmc   +1 more source

Cost-Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Cancer Treatment: A Systematic Review. [PDF]

Front Pharmacol, 2022
Chan VKY, Yang R, Wong ICK, Li X.
europepmc   +1 more source

Radiation-induced neuroinflammation: a potential protective role for poly(ADP-ribose) polymerase inhibitors? [PDF]

Neurooncol Adv, 2022
Gutierrez-Quintana R, Walker DJ, Williams KJ, Forster DM, Chalmers AJ.   +4 more
europepmc   +1 more source

An attempt to establish real-world databases of poly(ADP-ribose) polymerase inhibitors for advanced or recurrent epithelial ovarian cancer: the Japanese Gynecologic Oncology Group. [PDF]

J Gynecol Oncol, 2023
Shimada M, Yoshihara K, Tanigawa T, Nomura H, Hamanishi J, Fujiwara S, Tanabe H, Kajiyama H, Mandai M, Aoki D, Enomoto T, Okamoto A.   +11 more
europepmc   +1 more source

Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse. [PDF]

J Ovarian Res, 2023
Ma Y, Liu J, Li N, Bu H, Huang Y, Jin C, Wen H, Feng S, Zhang H, Yang X, Kong B, Wu L, Song K.   +12 more
europepmc   +1 more source

Recurrent patterns and prognostic factors based on CA-125 and RECIST progression in ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors. [PDF]

J Ovarian Res
Zhang B, Lv W, Fu Z, Zhou Y, Du J, Yao Q, Qian Q, Bu H.   +7 more
europepmc   +1 more source

Clinical implications and practical considerations for poly-ADP-ribose polymerase inhibitors as a new horizon for the management of urothelial carcinoma of the bladder. [PDF]

Investig Clin Urol, 2022
Lee HW, Seo HK.
europepmc   +1 more source

Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations. [PDF]

Front Pharmacol, 2021
Xu Q, Li Z.
europepmc   +1 more source